LIQUICLEN 200MCG / ML | 60ML

Clenbuterol belongs to the class beta-2 adrenergic agonists It is a sympathomimetic amine that acts on the adrenergic receptors and increases sympathetic activity. It was first developed by a German pharmaceutical to design a bronchodilator. It was marketed under the brand name Ventipulinium to treat respiratory disorders, such as asthma in horses.

Later, researchers found that it can boost the performance of racehorses. This discovery led to the ban of clenbuterol by the World Anti-Doping Agency. Furthermore, it is not approved by the US Food and Drug Administration for use in humans. At Pinnacle Peptides, clenbuterol for sale is exclusively available for research and educational institutions.

From Pubchem

IUPAC Name: 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol
Synonyms: Planipart, Clenbuterolum,
Molecular Formula: C12H18Cl2N2O
Molecular Weight: 277.19 g/mol
CAS number: 37148-27-9
PubChem CID: 2783

Clenbuterol is an agonist of beta-2 adrenergic receptors. These receptors are located on the smooth muscles of various tissues, including bronchioles, uterus and blood vessels. The binding of the drug to the receptor activates adenyl cyclase, an enzyme responsible for the conversion of ATP into cAMP. The increased concentration of cAMP in the cells leads to the relaxation of smooth muscles in bronchioles.

Plus, it has also been shown to stimulate CNS through activity on beta-1 and beta-2 receptors, resulting in increased blood pressure and heart rate. Research shows that clenbuterol offers more selectivity as compared to salbutamol. Furthermore, its results are more potent and long-lasting.

1. Chronic Obstructive Pulmonary Diseases

COPD is a group of progressive lung disorders that obstruct air flow, making it difficult to breathe. Various studies on human and animal models confirm the effectiveness of clenbuterol in treating respiratory disorders. Researchers designed a study to check the efficacy of this drug in the management of asthma in children. The results found that clenbuterol showed substantial effects as compared to the placebo. Furthermore, a single dose of 1ug/kg was found to be most successful in children with a favourable risk/benefit ratio [1].

2. Muscle mass

In addition to bronchodilation, clenbuterol has also been shown to exert anabolic effects. For the time being, it was thought that these effects are independent of beta-2 adrenergic receptors. However, research conducted on rats found contradictory results. Administration of clenbuterol (4mg/kg) resulted in increased protein synthesis, mRNA content and gastrocnemius muscle mass in rats. However, when the researchers administered beta-2 antagonists, these effects were diminished. This indicates that clenbuterol mediates anabolic effects through beta-2 adrenergic receptors [2].

Furthermore, one study was designed to compare the effect of clenbuterol and salbutamol on muscle mass in old and young rats. The researchers found that both drugs had the same effect on muscle mass, but clenbuterol greatly influenced protein synthesis as compared to salbutamol. Based on these findings, researchers suggested that both drugs can be used to prevent muscle loss associated with declining age [3]. These results are also confirmed by randomized clinical trials in humans, concluding that the clenbuterol can significantly boost lean muscle mass and improve lean/fat ratio [4].

3. Weight loss

Clenbuterol is one of the drugs that are widely misused by people for weight loss. There are not many human studies to confirm this effect. A study conducted on horses found that clenbuterol resulted in a significant reduction in fat content, with a 12% decrease observed in working horses and an 8% decrease in non-working horses [5].

The increased weight loss effect of clenbuterol might be attributed to its ability to stimulate thermogenesis. Increased heat production in the body leads to enhanced utilization of calories. Additionally, it possesses lipolytic properties, converting triglycerides into free fatty acids. In a study involving young men, clenbuterol intake was associated with a 21% increase in energy expenditure and a 39% rise in fat oxidation [6].

4. Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis(ALS) is a progressive neurodegenerative disease that affects the nerve cells in the brain and spinal cord. It primarily targets motor neurons, thus leading to loss of motor function and muscle weakness. Clenbuterol has been shown to have neuroprotective and muscle-strengthening effects, thus it might be able to resolve the symptoms of ALS. A small open-label trial found that clenbuterol at the dose of 40-80 ug slowed down the progression of disease [7].

Clenbuterol is a beta-2 adrenergic agonist primarily used for the treatment of bronchospasm in horses. It has not been approved by the FDA for use in human. It has more selectivity and pronounced effect compared to the salbutamol. It has been shown to increase muscle mass and improve lean/fat ratio. It might alleviate the symptoms of ALS, but further research is needed to confirm these effects. We don’t support its unwarranted use and offer liquid clenbuterol purchase solely for research. Only buy clenbuterol if you are an authorized researcher.

1. Boner, A.L., et al., bronchodilating activity of oral clenbuterol in asthmatic children after a single administration of different dosages. Pediatric Pulmonology, 1987. 3(1): p. 34-37.
2. Choo, J.J., M.A. Horan, R.A. Little, and N.J. Rothwell, Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. American Journal of Physiology-Endocrinology and Metabolism, 1992. 263(1): p. E50-E56.
3. Carter, W.J. and M.E. Lynch, Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism, 1994. 43(9): p. 1119-1125.
4. Kamalakkannan, G., et al., Clenbuterol Increases Lean Muscle Mass but Not Endurance in Patients With Chronic Heart Failure. The Journal of Heart and Lung Transplantation, 2008. 27(4): p. 457-461.
5. Nolen-Walston, R.D., et al., Effect of long-term oral administration of a low dosage of clenbuterol on body fat percentage in working and nonworking adult horses. Am J Vet Res, 2015. 76(5): p. 460-6.
6. Jessen, S., et al., Beta2-adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. Drug Testing and Analysis, 2020. 12(5): p. 610-618.
7. Li, X., et al., Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. J Clin Neuromuscul Dis, 2023. 24(4): p. 214-221.